Julia A. Haller's most recent trade in Bristol-Myers Squibb Co. was a trade of 20,460 Option (right to buy) done . Disclosure was reported to the exchange on June 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | Julia A. Haller | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 20,460 | 0 | - | - | Option (right to buy) | |
| Bristol-Myers Squibb | Julia A. Haller | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.76 per share. | 15 Jun 2026 | 20,460 | 34,079 (0%) | 0% | 53.8 | 1,099,930 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2026 | 3,996 | 37,903 | - | - | Deferred Share Units | |
| Outlook Therapeutics Inc | Julia A. Haller | Director | 01 Oct 2025 | 286,734 | 286,734 | - | - | Stock Option (Right to Buy) | ||
| Outlook Therapeutics Inc | Julia A. Haller | Director | 01 Oct 2025 | 58,648 | 58,648 | - | - | Stock Option (Right to Buy) | ||
| Bristol-Myers Squibb | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 3,562 | 32,223 | - | - | Deferred Share Units | |
| Outlook Therapeutics Inc | Julia A. Haller | Director | 01 Oct 2024 | 56,636 | 56,636 | - | - | Stock Option (Right to Buy) | ||
| Outlook Therapeutics Inc | Julia A. Haller | Director | 01 Oct 2024 | 47,232 | 47,232 | - | - | Stock Option (Right to Buy) | ||
| Outlook Therapeutics Inc | Julia A. Haller | Director | 01 Oct 2024 | 12,082 | 12,082 | - | - | Stock Option (Right to Buy) | ||
| Outlook Therapeutics Inc | Julia A. Haller | Director | 07 Mar 2024 | 94,441 | 94,441 | - | - | Stock Option (Right to Buy) | ||
| Bristol-Myers Squibb | Julia Haller A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 4,314 | 27,341 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb | A. Haller Julia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2023 | 706 | 22,746 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2023 | 624 | 21,797 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 553 | 20,978 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 486 | 20,255 | - | - | Deferred Share Units | |
| Outlook Therapeutics Inc | Julia A. Haller | Director | 29 Mar 2023 | 41,065 | 41,065 | - | - | Stock Option (Right to Buy) | ||
| Bristol-Myers Squibb | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 2,807 | 19,768 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2022 | 469 | 16,826 | - | - | Deferred Share Units | |
| Outlook Therapeutics Inc | Julia A. Haller | Director | 05 Oct 2022 | 42,239 | 42,239 | - | - | Stock Option (Right to Buy) | ||
| Bristol-Myers Squibb | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 474 | 16,244 | - | - | Deferred Share Units | |
| Outlook Therapeutics Inc | Julia A. Haller | Director | 11 Aug 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | ||
| Bristol-Myers Squibb | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2022 | 438 | 15,654 | - | - | Deferred Share Units | |
| Hyperion DeFi Inc | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 30,769 | 30,769 | - | - | Stock Option (right to buy) | |
| Hyperion DeFi Inc | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 22,222 | 30,408 (0%) | 0% | 0 | Common Stock, par value $.0001 | |
| Bristol-Myers Squibb | Julia A. Haller | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2022 | 2,949 | 0 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Julia A. Haller | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2022 | 2,949 | 13,619 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 462 | 15,107 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 3,067 | 14,645 | - | - | Deferred Share Units | |
| Bristol-Myers Squibb | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2021 | 521 | 11,482 | - | - | Deferred Share Units | |
| Hyperion DeFi Inc | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 9,653 | 9,653 | - | - | Stock Option (right to buy) | |
| Hyperion DeFi Inc | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 6,963 | 8,186 (0%) | 0% | 0 | Common Stock, par value $.0001 | |
| Bristol-Myers Squibb | Julia A. Haller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2021 | 549 | 10,870 | - | - | Deferred Share Units |